A Phase 3 interventional study of Beclomethasone dipropionate hydrofluoroalkane HFA Nasal Aerosol and Placebo Nasal Aerosol in Rhinitis, Allergic, Perennial, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 35 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2012-05-23.
Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies in Rhinitis, Allergic, Perennial with a site in United States — none open to participants now, 1 under way, 1 of them phase 3. Rhinitis, Allergic, Perennial · United States.
Among the 60 studies in Rhinitis, Allergic, Perennial with a site in United States, this one is the 18th largest by enrollment of the 57 interventional ones that give a count, is one of 5 that started in 2010, is one of 33 in phase 3, and was the 43rd registered.
178 studies on the registry are indexed under Rhinitis, Allergic, Perennial; 9 are open to participants now.
Browse Rhinitis, Allergic, Perennial studies →None of the 60 studies in Rhinitis, Allergic, Perennial with a site in United States is open now. The open studies under Rhinitis, Allergic, Perennial, anywhere →
Of the 3 Rhinitis, Allergic, Perennial studies recruiting now, none set no upper age limit and 3 stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 5 · Phase 3 33 · Phase 4 14
First in 2000; this study’s year is marked. 5 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 474 is above the median of 135 across 157 interventional studies indexed under Rhinitis, Allergic, Perennial.
Median enrollment 301 across the 57 interventional studies, 824 across the 3 observational. Of the 58 that completed or were terminated, 37 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 60 have an industry lead sponsor. The 10 most frequent:
This study is registered under Teva Branded Pharmaceutical Products R&D, Inc., one of the names counted as Teva Pharmaceutical Industries, Ltd.. Under that name alone:
Teva Branded Pharmaceutical Products R&D, Inc. is the lead sponsor of 206 studies on the registry; none are open to participants now.
Of its 49 completed or terminated interventional studies of FDA-regulated products, 47 (96%) have results posted.
Teva Pharmaceutical Industries, Ltd. has 4 studies filed under Rhinitis, Allergic, Perennial — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 60 studies in Rhinitis, Allergic, Perennial with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to assess the efficacy and safety of an investigational nasal aerosol compared with placebo nasal aerosol in the treatment of perennial allergic rhinitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
During the 6-week double-blind Treatment Period participants self-administered 4 actuations (two per nostril) of 80 µg BDP HFA once daily.
Drug: Beclomethasone dipropionate hydrofluoroalkane HFA Nasal Aerosol
During the 6-week double-blind Treatment Period participants self-administered four actuations (two per nostril) of placebo HFA once daily.
Drug: Placebo Nasal Aerosol
Beclomethasone dipropionate (BDP) Hydrofluoroalkane (HFA) Nasal Aerosol
Also known as: QNASL(TM)
HFA Vehicle Aerosol
Change From Baseline in Average AM and PM Reflective Total Nasal Symptom Score (rTNSS) Over the Six-week Treatment Period
Participants recorded the severity of their nasal symptoms (sneezing, runny nose, itchy nose and nasal congestion) over the past 12 hours twice daily (AM \& PM) using the following scale: 0=absent (no sign/symptom); 1=mild (sign/symptom present, awareness, easily tolerated); 2=moderate (awareness of sign/symptom, bothersome but tolerable); 3=severe (sign/symptoms hard to tolerate, interfere with daily activities and/or sleeping). The total nasal symptom score (sum of 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from Baseline score indicates symptom improvement.
Time frame: Baseline (Days -3 to 0) and Days 1-43 (6-week Treatment Period)
Change From Baseline in Average AM and PM Instantaneous Total Nasal Symptom Score (iTNSS) Over the Six-week Treatment Period
Participants recorded the severity of their nasal symptoms (sneezing, runny nose, itchy nose and nasal congestion) over the 10 minutes prior to assessment twice daily (AM \& PM) using the following scale: 0=absent (no sign/symptom); 1=mild (sign/symptom present, easily tolerated); 2=moderate (awareness of symptoms, bothersome but tolerable); 3=severe (symptoms hard to tolerate, interfere with daily activities and/or sleeping). The total nasal symptom score (sum of the 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from Baseline score indicates symptom improvement.
Time frame: Baseline (Days -3 to 0) and Days 1-43 (6-week Treatment Period)
Change From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)
The adult RQLQ has 28 questions in 7 domains (activities, sleep, non-nose/eye symptoms, practical problems, nasal symptoms, eye symptoms, and emotional). Participants were asked to recall their experiences during the previous week and to give their responses on a 7-point scale (0 = Least severe to 6 = Extremely severe). The overall RQLQ score is the mean of all 28 responses, and ranges from 0 to 7. A negative change from Baseline score indicates improvement.
Time frame: Baseline and Week 6
A total of 675 patients were screened and 574 patients were enrolled in the study and participated in the Run-in Period. Of the 574 enrolled patients, 474 were randomized to study treatment.
| Milestone | BDP HFA 320 µg/Day | Placebo |
|---|---|---|
| Started | 236 | 238 |
| Intent to treat population | 232 | 234 |
| Completed | 221 | 216 |
| Not completed | 15 | 22 |
| Withdrew: Adverse event | 1 | 7 |
| Withdrew: Withdrawal by subject | 6 | 6 |
| Withdrew: Pregnancy | 1 | 0 |
| Withdrew: Lost to follow-up | 5 | 2 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Other | 1 | 6 |
Participants recorded the severity of their nasal symptoms (sneezing, runny nose, itchy nose and nasal congestion) over the past 12 hours twice daily (AM \& PM) using the following scale: 0=absent (no sign/symptom); 1=mild (sign/symptom present, awareness, easily tolerated); 2=moderate (awareness of sign/symptom, bothersome but tolerable); 3=severe (sign/symptoms hard to tolerate, interfere with daily activities and/or sleeping). The total nasal symptom score (sum of 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from Baseline score indicates symptom improvement.
| units on a scale | BDP HFA 320 µg/Day | Placebo |
|---|---|---|
| Change From Baseline in Average AM and PM Reflective Total Nasal Symptom Score (rTNSS) Over the Six-week Treatment Period | -2.5 ± 0.14 | -1.6 ± 0.14 |
Participants recorded the severity of their nasal symptoms (sneezing, runny nose, itchy nose and nasal congestion) over the 10 minutes prior to assessment twice daily (AM \& PM) using the following scale: 0=absent (no sign/symptom); 1=mild (sign/symptom present, easily tolerated); 2=moderate (awareness of symptoms, bothersome but tolerable); 3=severe (symptoms hard to tolerate, interfere with daily activities and/or sleeping). The total nasal symptom score (sum of the 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from Baseline score indicates symptom improvement.
| units on a scale | BDP HFA 320 µg/Day | Placebo |
|---|---|---|
| Change From Baseline in Average AM and PM Instantaneous Total Nasal Symptom Score (iTNSS) Over the Six-week Treatment Period | -2.1 ± 0.13 | -1.4 ± 0.13 |
The adult RQLQ has 28 questions in 7 domains (activities, sleep, non-nose/eye symptoms, practical problems, nasal symptoms, eye symptoms, and emotional). Participants were asked to recall their experiences during the previous week and to give their responses on a 7-point scale (0 = Least severe to 6 = Extremely severe). The overall RQLQ score is the mean of all 28 responses, and ranges from 0 to 7. A negative change from Baseline score indicates improvement.
| units on a scale | BDP HFA 320 µg/Day | Placebo |
|---|---|---|
| Change From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) | -1.5 ± 0.14 | -0.9 ± 0.14 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BDP HFA 320 µg/Day | — | 1/236 (0.4%) | 14/236 (5.9%) |
| Placebo | — | 0/238 (0%) | 12/238 (5%) |
| Event | BDP HFA 320 µg/Day | Placebo |
|---|---|---|
| ArrhythmiaCardiac disorders | 1/236 | 0/238 |
| Event | BDP HFA 320 µg/Day | Placebo |
|---|---|---|
| Nasal discomfortRespiratory, thoracic and mediastinal disorders | 14/236 | 12/238 |
| Age Continuous(years) | BDP HFA 320 µg/Day | Placebo | Total |
|---|---|---|---|
| Mean | 36.8 ± 14.5 | 37.2 ± 13.7 | 37.0 ± 14.1 |
| Sex: Female, Male(Participants) | BDP HFA 320 µg/Day | Placebo | Total |
|---|---|---|---|
| Female | 158 | 161 | 319 |
| Male | 74 | 73 | 147 |
| Race/Ethnicity, Customized(participants) | BDP HFA 320 µg/Day | Placebo | Total |
|---|---|---|---|
| White | 186 | 185 | 371 |
| Black or African American | 40 | 40 | 80 |
| Asian | 6 | 5 | 11 |
| American Indian or Alaskan Native | 1 | 2 | 3 |
| Other | 1 | 6 | 7 |
| Race/Ethnicity, Customized(participants) | BDP HFA 320 µg/Day | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 26 | 30 | 56 |
| Not Hispanic or Latino | 206 | 204 | 410 |
| Region of Enrollment(participants) | BDP HFA 320 µg/Day | Placebo | Total |
|---|---|---|---|
| United States | 232 | 234 | 466 |
The record gives a start of May 2010, a primary completion of Oct 2010 and a completion of Oct 2010. It does not say whether these dates are actual or estimated.
Results were first posted in May 2012, 1 year 7 months after primary completion. A results delay was requested in Aug 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Beclomethasone
Rhinitis, Allergic, Perennial →
Teva Branded Pharmaceutical Products R&D, Inc. →